Colorectal News and Research

RSS

Amgen announces Phase 3 results evaluating Vectibix in combination with FOLFIRI chemotherapy

Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC.

22 Sep 2009

Patients with higher levels of vitamin D are less likely to die from skin cancer

New research shows higher levels of vitamin D may help improve survival for both bowel and skin cancer patients.

22 Sep 2009

Phase 1 clinical trial results evaluating ARIAD's investigational mTOR inhibitor ridaforolimus

ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced data from a Phase 1 clinical trial evaluating oral ridaforolimus, its investigational mTOR inhibitor, in combination with bevacizumab (Avastin®) in heavily pretreated patients with refractory metastatic solid tumors. The data were presented at the Joint Multidisciplinary Congress of the 15th annual European Cancer Organization (ECCO) and the 34th annual European Society of Medical Oncology (ESMO) taking place in Berlin, Germany.

21 Sep 2009

GI cancer detection simpler and cost-effective with new blood tests

Berlin, Germany: Promising results from two new blood tests that can aid in the early identification of patients with gastrointestinal (GI) cancers will be presented at Europe's largest cancer congress, ECCO 15 - ESMO 34 [1], in Berlin today (Monday September 21). The tests will make GI cancer detection simpler, cost-effective, and more acceptable to patients than current methods, the researchers say.

21 Sep 2009

Study reveals that GI cancer can be diagnosed using blood tests

...

21 Sep 2009

Jennerex raises funds through private placement for clinical development programs

Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical stage biopharmaceutical company developing a proprietary breakthrough product class of targeted oncolytic virus therapeutics, today announced the Second and final closing of a private placement financing with aggregate gross proceeds of US $5,611,475, exceeding the target of US $5 million.

19 Sep 2009

Phase I trial of NPC-1C to commence

Neogenix Oncology, Inc. (Neogenix) announced today that NPC-1C, the company’s first IND (Investigational New Drug Application) was granted permission by the Food and Drug Administration (FDA) for the company to begin a Phase I trial.

18 Sep 2009

Bayer HealthCare to present its clinical trial data at a joint Multidisciplinary Congress

Bayer HealthCare today announced that data from more than 30 clinical trials evaluating three products in the company's oncology portfolio - Nexavar(R) (sorafenib) tablets, regorafenib (BAY 73-4506) and Alpharadin(TM) - will be presented at the joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress, September 20-24, 2009 in Berlin, Germany.

17 Sep 2009

Diagnocure reports third-quarter fiscal 2009 results

DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced revenue of $396,468 and a net loss of $4,034,364 or $0.09 per share for the third quarter ending July 31, 2009.

17 Sep 2009

Amgen to present its four Phase 3 clinical trial results

Amgen today announced it will present detailed data from four Phase 3 studies as well as other data at the ECCO 15 - ESMO 34 European Multidisciplinary Congress, September 20 - 24, 2009 in Berlin, Germany.

16 Sep 2009

Immune response at tumour site predicts cancer progression in colorectal cancer patients

The immune reaction at tumour site determines cancer evolution and clinical outcome in patients with colorectal cancer, regardless of the local extent and spread of the tumour, according to the findings of Jérôme Galon, INSERM Research Director, Paris, and co-workers.

16 Sep 2009

Hispanic/Latino Americans have a unique cancer risk profile, says report

The latest edition of Cancer Facts & Figures for Hispanics/Latinos reports that Hispanic/Latino Americans -the largest, fastest-growing, and youngest minority in the United States-have a unique cancer risk profile that requires a targeted approach to cancer prevention.

15 Sep 2009

Third-quarter fiscal 2009 results announced by DiagnoCure

15 Sep 2009

Trabedersen granted orphan drug designation from both FDA And EMEA for treating pancreatic carcinoma

The biopharmaceutical company Antisense Pharma GmbH has announced today that it has received orphan drug designation from both the European Medicines Agency EMEA and the US Food and Drug Administration FDA for its investigational drug trabedersen in the treatment of pancreatic carcinoma.

14 Sep 2009

Sanofi-aventis and Regeneron Pharmaceuticals discontinue Phase 3 trial of aflibercept

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. today announced the discontinuation of the Phase 3 trial that evaluated aflibercept (VEGF Trap) plus gemcitabine versus placebo plus gemcitabine for the first-line treatment of metastatic pancreatic cancer (VANILLA), based on the recommendations by an Independent Data Monitoring Committee (IDMC).

14 Sep 2009

Body mass in younger and older adulthood linked to prostate cancer risks

A team of scientists led by researcher Brenda Hernandez, Ph.D., M.P.H.-an assistant professor at the University of Hawai'i at Mānoa's Cancer Research Center of Hawai'i-has reported that body mass in younger and older adulthood, and weight gain between these life periods, may influence a man's risk for prostate cancer. This risk varies among different ethnic groups, according to findings reported in a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

14 Sep 2009

Abstracts on Merck Serono oncology treatments to be presented at ECCO and ESMO

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, continues to drive the global effort to ensure patients receive personalized cancer therapies. A total of 17 abstracts concerning Merck Serono oncology treatments will be presented at the joint 15th Congress of the European Cancer Organisation (ECCO) and 34th Congress of the European Society for Medical Oncology (ESMO), to be held in Berlin from 20-24 September 2009.

11 Sep 2009

Gastroenterologists applaud President's call for screening tests coverage

Gastrointestinal specialists from the American College of Gastroenterology applaud President Obama's call to cover preventive screening tests, such as breast cancer exams and colonoscopy. In his health care speech to a joint session of Congress last night, the President argued that "there's no reason we shouldn't be catching diseases like breast cancer and colon cancer before they get worse. That makes sense."

11 Sep 2009

GI Company's Phase II study demonstrates safety of rhITF oral spray formulation

Published today, as an original investigation, in the peer-reviewed Journal of Clinical Oncology, are statistically significant Phase II clinical results of The GI Company's lead clinical compound, rhITF (recombinant human Intestinal Trefoil Factor) oral spray. The article is titled, "A Phase II, Randomized, Double-blind, Placebo-Controlled Study of rhITF Oral Spray for Prevention of Oral Mucositis in Colorectal Cancer Patients Receiving 5-Fluorouracil-based Chemotherapy."

10 Sep 2009

Complete Genomics sequences and delivers 14 human genomes

Complete Genomics Inc., a third-generation human genome sequencing company, announced today that it has sequenced, analyzed and delivered 14 human genomes to customers since March 2009.

10 Sep 2009

Colorectal News and Research

Amgen announces Phase 3 results evaluating Vectibix in combination with FOLFIRI chemotherapy

Patients with higher levels of vitamin D are less likely to die from skin cancer

Phase 1 clinical trial results evaluating ARIAD's investigational mTOR inhibitor ridaforolimus

GI cancer detection simpler and cost-effective with new blood tests

Study reveals that GI cancer can be diagnosed using blood tests

Jennerex raises funds through private placement for clinical development programs

Phase I trial of NPC-1C to commence

Bayer HealthCare to present its clinical trial data at a joint Multidisciplinary Congress

Diagnocure reports third-quarter fiscal 2009 results

Amgen to present its four Phase 3 clinical trial results

Immune response at tumour site predicts cancer progression in colorectal cancer patients

Hispanic/Latino Americans have a unique cancer risk profile, says report

Third-quarter fiscal 2009 results announced by DiagnoCure

Trabedersen granted orphan drug designation from both FDA And EMEA for treating pancreatic carcinoma

Sanofi-aventis and Regeneron Pharmaceuticals discontinue Phase 3 trial of aflibercept

Body mass in younger and older adulthood linked to prostate cancer risks

Abstracts on Merck Serono oncology treatments to be presented at ECCO and ESMO

Gastroenterologists applaud President's call for screening tests coverage

GI Company's Phase II study demonstrates safety of rhITF oral spray formulation

Complete Genomics sequences and delivers 14 human genomes

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News